The disease duration of RA was longer in JAKi users than non-TNF inhibitor users (OR 1.05, CI 1.00–1.09) but the difference was marginal when compared with TNF inhibitor users (OR 1.03, CI 0.99–1.07). This evidence concerns the gene TNF and rheumatoid arthritis.